US 11,708,610 B2
Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
Olga Iakoubova, San Ramon, CA (US); James J. Devlin, Lafayette, CA (US); Zenta Tsuchihashi, Skillman, NJ (US); Peter Shaw, Yardley, PA (US); Lynn Marie Ploughman, Washington Crossing, PA (US); Kim E. Zerba, New Hope, PA (US); Koustubh Ranade, Princeton, IN (US); and Todd Kirchgessner, North Whales, PA (US)
Assigned to Celera Corporation, San Juan Capistrano, CA (US)
Filed by CELERA CORPORATION, San Juan Capistrano, CA (US); and BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
Filed on Feb. 26, 2021, as Appl. No. 17/186,574.
Application 17/186,574 is a division of application No. 15/894,253, filed on Feb. 12, 2018, granted, now 10,982,281.
Application 15/894,253 is a division of application No. 15/168,632, filed on May 31, 2016, granted, now 9,932,637, issued on Apr. 3, 2018.
Application 14/045,416 is a division of application No. 12/683,099, filed on Jan. 6, 2010, abandoned.
Application 12/683,099 is a division of application No. 10/995,561, filed on Nov. 24, 2004, abandoned.
Application 15/168,632 is a continuation of application No. 14/045,416, filed on Oct. 3, 2013, abandoned.
Claims priority of provisional application 60/568,219, filed on May 6, 2004.
Claims priority of provisional application 60/524,882, filed on Nov. 26, 2003.
Prior Publication US 2021/0332434 A1, Oct. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12P 19/34 (2006.01); C12Q 1/6883 (2018.01); A61K 31/225 (2006.01); G01N 33/68 (2006.01); C07K 16/28 (2006.01); A61K 31/22 (2006.01)
CPC C12Q 1/6883 (2013.01) [A61K 31/22 (2013.01); A61K 31/225 (2013.01); C07K 16/28 (2013.01); G01N 33/6893 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/172 (2013.01); G01N 2800/32 (2013.01); G01N 2800/324 (2013.01)] 14 Claims
 
1. A method for reducing the risk of myocardial infarction in a human, the method comprising:
a) testing nucleic acid from said human for a polymorphism in gene NPC1 as represented by position 101 of SEQ ID NO:59198 or its complement by contacting said nucleic acid with an oligonucleotide that specifically hybridizes to G at said position 101 of SEQ ID NO:59198 or C at said complement;
b) detecting said G or said C;
c) identifying said human as having an increased risk for myocardial infarction or as being responsive to statin treatment for reducing their risk of myocardial infarction due to the presence of said G or said C; and
d) administering a statin to said human.